The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report

Liquid biopsy is recommended to diagnose molecular resistance to targeted therapy in patients with lung cancer. Nevertheless, not all jurisdictions provide funding and patient access. We report patients’ perceived value of liquid biopsy in targeted therapy resistance. Canadian patients participating...

Full description

Saved in:

Bibliographic Details
Published in:	JTO clinical and research reports Vol. 5; no. 1; p. 100615
Main Authors:	Chen, Kaitlin H., Barnes, Tristan A., Laskin, Janessa, Cheema, Parneet, Liu, Geoffrey, Iqbal, Mussawar, Rothenstein, Jeffrey, Burkes, Ronald, Tsao, Ming-Sound, Leighl, Natasha B.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-01-2024 Elsevier
Subjects:	Brief Report Liquid biopsy Non–small cell lung cancer T790M Willingness-to-pay Liquid biopsy Non–small cell lung cancer T790M Willingness-to-pay
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Liquid biopsy is recommended to diagnose molecular resistance to targeted therapy in patients with lung cancer. Nevertheless, not all jurisdictions provide funding and patient access. We report patients’ perceived value of liquid biopsy in targeted therapy resistance. Canadian patients participating in a national EGFR T790M liquid biopsy validation study completed structured interviews measuring perceived value and willingness-to-pay for plasma circulating tumor DNA testing as an alternative to tumor biopsy using open-ended and iterative bidding approaches. A total of 60 patients with advanced lung cancer participated with a median age of 64 years (range: 31–87 y); 69% were Asian and 45% female. All had received prior EGFR tyrosine kinase inhibitor; 17% also received chemotherapy. All patients preferred to have plasma testing over repeat tumor biopsy. In the context of the Canadian publicly funded system, patients estimated that a median of 300 (interquartile range: 150–800) Canadian dollars was a reasonable price to pay for liquid biopsy. Patients were personally willing to pay a median 100 (interquartile range: 33–350) Canadian dollars. In a system that covers the cost of standard diagnostic tests, patients with lung cancer indicated high willingness-to-pay out-of-pocket for liquid biopsy in the setting of acquired targeted therapy resistance. Patients have high perceived value of plasma genotyping and prefer it to repeat tumor biopsy.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Drs. Chen and Barnes contributed equally to this work.
ISSN:	2666-3643 2666-3643
DOI:	10.1016/j.jtocrr.2023.100615